Global Dengue Vaccines

Dengue Vaccines Comprehensive Study by Application (Prevention of dengue, Enhanced the immunity), End Users (Government organizations, Medical clinics, Non-profit Organization, Diagnostic centers), Vaccines (Live Attenuated Vaccines, Chimeric Live Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, Nucleic Acid-Based Vaccines) Players and Region - Global Market Outlook to 2028

Dengue Vaccines Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Dengue Vaccines
Dengue is a viral disease transmitted by infected mosquitoes, particularly female mosquito of Aedes aegypti responsible vector to transmit the virus that causes dengue. Dengue causes sudden fever and pain in the joints. While vaccines are preventive measures taken to cure any disease by facilitating immunity to develop protection from disease. It is a biological preparation that provides active acquired immunity, vaccines are consisting of substance-related to disease-causing microorganism and are sometimes made from weak or killed forms of the microbe, its toxins, or its proteins. Dengue vaccine is mainly CYD tetravalent dengue vaccine from Sanofi Pasteur (France)is leading for dengue vaccines. A live attenuated vaccine known as Dengvaxia, developed by Sanofi, launched and approved license in 2015. Dengvaxia is a mixture of four monovalent chimeric vaccine viruses, CYD-1, CYD-2, CYD-3, and CYD-4, produced using Vero cells. These four CYDs are based on the yellow fever virus (YFV) 17D vaccine vector backbone. First licenses approved in Mexico in 2015 for 9-45 individuals for 20 countries.

AttributesDetails
Study Period2018-2028
Base Year2022
UnitValue (USD Million)


The leading pharmaceutical companies are working on their research and development team to clear all the clinical trials and get approval from the FDA to launch its vaccines. Therefore the competition is now with research teams of different manufactures to get the company profit and business. There is also an option available like mergers and acquisitions of a different firm to enhanced the research and technological enhancement of the companies. Analyst at AMA Research estimates that Asia Pacific Players will contribute the maximum growth to Global Dengue Vaccines market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Sanofi Pasteur Inc (France), Merck & Co Inc (United States), GlaxoSmithKline (United Kingdom ), Pfizer (United States), Instituto Butantan (Brazil), Takeda Pharmaceutical Company Limited (Japan), Sun Pharmaceutical Industries Limited (India), GeneOne Life Science Inc (South Korea), Medigen Vaccine Biologics Corporation (China) and Merck Sharp & Dohme (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Vabiotec (Vietnam) and Panacea Biotec Limited (India).

Segmentation Overview
AMA Research has segmented the market of Global Dengue Vaccines market by , Application (Prevention of dengue and Enhanced the immunity) and Region.



On the basis of geography, the market of Dengue Vaccines has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by End Users, the sub-segment i.e. Government organizations will boost the Dengue Vaccines market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Vaccines, the sub-segment i.e. Live Attenuated Vaccines will boost the Dengue Vaccines market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Two New Live Attenuated Dengue Vaccines Are Currently In Phase Iii Efficacy Trials and Dsv4 Process Development And Scale-Up Work Are Currently In Progress

Market Growth Drivers:
Growing Demand due to Rising in Infection Level

Challenges:
Dengue Vaccines Are Challenged By Critical Issues Like Lack Of Animal Models For The Disease And Absence Of Suitable Markers Of Protective Immunity, New Advances In Dengue Pathogenesis And Immune Response Will Shed Light On The Approach Needed To Make An Ideal Dengue Vaccine and Dengue Vaccines Banned In Philippines Due To Controversy

Restraints:
The Lack Of An Appropriate Animal Model That Elucidates The Pathogenesis, Immune Response And Clinical Course Of Dengue Infection In Humans, Unsuitable For Studying Immune Responses In Dengue Vaccine Pre-Clinical Trials and Sometimes Side Effects Related To Dengue Vaccines Are Severe

Opportunities:
Highly Demanded In Rainy Season

Market Leaders and their expansionary development strategies
In July 2023, Takeda Pharmaceutical Company and PATH has Announced a partnership to accelerate access to Takeda's dengue vaccine, TAK-003, in low- and middle-income countries (LMICs). This partnership will focus on supporting regulatory approval, building healthcare worker capacity, and increasing vaccine awareness in LMICs.
In October 2023, Takeda Pharmaceutical Company has Announced positive Phase III clinical trial results for its dengue vaccine candidate, TAK-003. The vaccine demonstrated 80.2% efficacy against all dengue serotypes in 6-16 year olds, and 90.1% efficacy in those who had previously been infected with dengue.
On 1st May 2019, the FDA approves the first vaccine for dengue fever, but with major restrictions. The Food and Drug Administration approved the first vaccine against dengue fever, one that protects against a common disease but has generated significant controversy due to evidence it can increase the risk of severe infection in some people. Dengvaxia was licensed in 2015. But it caused a major scandal two years ago in the Philippines. After nearly a million Filipino children had been vaccinated with Dengvaxia, the drug's manufacturer, Sanofi, announced that the inoculation might make dengue worse in some people.

Key Target Audience
Manufacturers, Hospital and diagnostic centers, Distributors/Suppliers/Wholesalers, Government sector, Research firms, Clinical Trial Centres and Downstream Vendors

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Application
  • Prevention of dengue
  • Enhanced the immunity
By End Users
  • Government organizations
  • Medical clinics
  • Non-profit Organization
  • Diagnostic centers

By Vaccines
  • Live Attenuated Vaccines
  • Chimeric Live Attenuated Vaccines
  • Inactivated Vaccines
  • Subunit Vaccines
  • Nucleic Acid-Based Vaccines

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing Demand due to Rising in Infection Level
    • 3.3. Market Challenges
      • 3.3.1. Dengue Vaccines Are Challenged By Critical Issues Like Lack Of Animal Models For The Disease And Absence Of Suitable Markers Of Protective Immunity
      • 3.3.2. New Advances In Dengue Pathogenesis And Immune Response Will Shed Light On The Approach Needed To Make An Ideal Dengue Vaccine
      • 3.3.3. Dengue Vaccines Banned In Philippines Due To Controversy
    • 3.4. Market Trends
      • 3.4.1. Two New Live Attenuated Dengue Vaccines Are Currently In Phase Iii Efficacy Trials
      • 3.4.2. Dsv4 Process Development And Scale-Up Work Are Currently In Progress
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Dengue Vaccines, by Application, End Users, Vaccines and Region (value, volume and price ) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Dengue Vaccines (Value)
      • 5.2.1. Global Dengue Vaccines by: Application (Value)
        • 5.2.1.1. Prevention of dengue
        • 5.2.1.2. Enhanced the immunity
      • 5.2.2. Global Dengue Vaccines by: End Users (Value)
        • 5.2.2.1. Government organizations
        • 5.2.2.2. Medical clinics
        • 5.2.2.3. Non-profit Organization
        • 5.2.2.4. Diagnostic centers
      • 5.2.3. Global Dengue Vaccines by: Vaccines (Value)
        • 5.2.3.1. Live Attenuated Vaccines
        • 5.2.3.2. Chimeric Live Attenuated Vaccines
        • 5.2.3.3. Inactivated Vaccines
        • 5.2.3.4. Subunit Vaccines
        • 5.2.3.5. Nucleic Acid-Based Vaccines
      • 5.2.4. Global Dengue Vaccines Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Dengue Vaccines (Volume)
      • 5.3.1. Global Dengue Vaccines by: Application (Volume)
        • 5.3.1.1. Prevention of dengue
        • 5.3.1.2. Enhanced the immunity
      • 5.3.2. Global Dengue Vaccines by: End Users (Volume)
        • 5.3.2.1. Government organizations
        • 5.3.2.2. Medical clinics
        • 5.3.2.3. Non-profit Organization
        • 5.3.2.4. Diagnostic centers
      • 5.3.3. Global Dengue Vaccines by: Vaccines (Volume)
        • 5.3.3.1. Live Attenuated Vaccines
        • 5.3.3.2. Chimeric Live Attenuated Vaccines
        • 5.3.3.3. Inactivated Vaccines
        • 5.3.3.4. Subunit Vaccines
        • 5.3.3.5. Nucleic Acid-Based Vaccines
      • 5.3.4. Global Dengue Vaccines Region
        • 5.3.4.1. South America
          • 5.3.4.1.1. Brazil
          • 5.3.4.1.2. Argentina
          • 5.3.4.1.3. Rest of South America
        • 5.3.4.2. Asia Pacific
          • 5.3.4.2.1. China
          • 5.3.4.2.2. Japan
          • 5.3.4.2.3. India
          • 5.3.4.2.4. South Korea
          • 5.3.4.2.5. Taiwan
          • 5.3.4.2.6. Australia
          • 5.3.4.2.7. Rest of Asia-Pacific
        • 5.3.4.3. Europe
          • 5.3.4.3.1. Germany
          • 5.3.4.3.2. France
          • 5.3.4.3.3. Italy
          • 5.3.4.3.4. United Kingdom
          • 5.3.4.3.5. Netherlands
          • 5.3.4.3.6. Rest of Europe
        • 5.3.4.4. MEA
          • 5.3.4.4.1. Middle East
          • 5.3.4.4.2. Africa
        • 5.3.4.5. North America
          • 5.3.4.5.1. United States
          • 5.3.4.5.2. Canada
          • 5.3.4.5.3. Mexico
    • 5.4. Global Dengue Vaccines (Price)
  • 6. Dengue Vaccines: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Sanofi Pasteur Inc (France)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Merck & Co Inc (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. GlaxoSmithKline (United Kingdom )
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Pfizer (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Instituto Butantan (Brazil)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Takeda Pharmaceutical Company Limited (Japan)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Sun Pharmaceutical Industries Limited (India)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. GeneOne Life Science Inc (South Korea)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Medigen Vaccine Biologics Corporation (China)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Merck Sharp & Dohme (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Dengue Vaccines Sale, by Application, End Users, Vaccines and Region (value, volume and price ) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Dengue Vaccines (Value)
      • 7.2.1. Global Dengue Vaccines by: Application (Value)
        • 7.2.1.1. Prevention of dengue
        • 7.2.1.2. Enhanced the immunity
      • 7.2.2. Global Dengue Vaccines by: End Users (Value)
        • 7.2.2.1. Government organizations
        • 7.2.2.2. Medical clinics
        • 7.2.2.3. Non-profit Organization
        • 7.2.2.4. Diagnostic centers
      • 7.2.3. Global Dengue Vaccines by: Vaccines (Value)
        • 7.2.3.1. Live Attenuated Vaccines
        • 7.2.3.2. Chimeric Live Attenuated Vaccines
        • 7.2.3.3. Inactivated Vaccines
        • 7.2.3.4. Subunit Vaccines
        • 7.2.3.5. Nucleic Acid-Based Vaccines
      • 7.2.4. Global Dengue Vaccines Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Dengue Vaccines (Volume)
      • 7.3.1. Global Dengue Vaccines by: Application (Volume)
        • 7.3.1.1. Prevention of dengue
        • 7.3.1.2. Enhanced the immunity
      • 7.3.2. Global Dengue Vaccines by: End Users (Volume)
        • 7.3.2.1. Government organizations
        • 7.3.2.2. Medical clinics
        • 7.3.2.3. Non-profit Organization
        • 7.3.2.4. Diagnostic centers
      • 7.3.3. Global Dengue Vaccines by: Vaccines (Volume)
        • 7.3.3.1. Live Attenuated Vaccines
        • 7.3.3.2. Chimeric Live Attenuated Vaccines
        • 7.3.3.3. Inactivated Vaccines
        • 7.3.3.4. Subunit Vaccines
        • 7.3.3.5. Nucleic Acid-Based Vaccines
      • 7.3.4. Global Dengue Vaccines Region
        • 7.3.4.1. South America
          • 7.3.4.1.1. Brazil
          • 7.3.4.1.2. Argentina
          • 7.3.4.1.3. Rest of South America
        • 7.3.4.2. Asia Pacific
          • 7.3.4.2.1. China
          • 7.3.4.2.2. Japan
          • 7.3.4.2.3. India
          • 7.3.4.2.4. South Korea
          • 7.3.4.2.5. Taiwan
          • 7.3.4.2.6. Australia
          • 7.3.4.2.7. Rest of Asia-Pacific
        • 7.3.4.3. Europe
          • 7.3.4.3.1. Germany
          • 7.3.4.3.2. France
          • 7.3.4.3.3. Italy
          • 7.3.4.3.4. United Kingdom
          • 7.3.4.3.5. Netherlands
          • 7.3.4.3.6. Rest of Europe
        • 7.3.4.4. MEA
          • 7.3.4.4.1. Middle East
          • 7.3.4.4.2. Africa
        • 7.3.4.5. North America
          • 7.3.4.5.1. United States
          • 7.3.4.5.2. Canada
          • 7.3.4.5.3. Mexico
    • 7.4. Global Dengue Vaccines (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Dengue Vaccines: by Application(USD Million)
  • Table 2. Dengue Vaccines Prevention of dengue , by Region USD Million (2017-2022)
  • Table 3. Dengue Vaccines Enhanced the immunity , by Region USD Million (2017-2022)
  • Table 4. Dengue Vaccines: by End Users(USD Million)
  • Table 5. Dengue Vaccines Government organizations , by Region USD Million (2017-2022)
  • Table 6. Dengue Vaccines Medical clinics , by Region USD Million (2017-2022)
  • Table 7. Dengue Vaccines Non-profit Organization , by Region USD Million (2017-2022)
  • Table 8. Dengue Vaccines Diagnostic centers , by Region USD Million (2017-2022)
  • Table 9. Dengue Vaccines: by Vaccines(USD Million)
  • Table 10. Dengue Vaccines Live Attenuated Vaccines , by Region USD Million (2017-2022)
  • Table 11. Dengue Vaccines Chimeric Live Attenuated Vaccines , by Region USD Million (2017-2022)
  • Table 12. Dengue Vaccines Inactivated Vaccines , by Region USD Million (2017-2022)
  • Table 13. Dengue Vaccines Subunit Vaccines , by Region USD Million (2017-2022)
  • Table 14. Dengue Vaccines Nucleic Acid-Based Vaccines , by Region USD Million (2017-2022)
  • Table 15. South America Dengue Vaccines, by Country USD Million (2017-2022)
  • Table 16. South America Dengue Vaccines, by Application USD Million (2017-2022)
  • Table 17. South America Dengue Vaccines, by End Users USD Million (2017-2022)
  • Table 18. South America Dengue Vaccines, by Vaccines USD Million (2017-2022)
  • Table 19. Brazil Dengue Vaccines, by Application USD Million (2017-2022)
  • Table 20. Brazil Dengue Vaccines, by End Users USD Million (2017-2022)
  • Table 21. Brazil Dengue Vaccines, by Vaccines USD Million (2017-2022)
  • Table 22. Argentina Dengue Vaccines, by Application USD Million (2017-2022)
  • Table 23. Argentina Dengue Vaccines, by End Users USD Million (2017-2022)
  • Table 24. Argentina Dengue Vaccines, by Vaccines USD Million (2017-2022)
  • Table 25. Rest of South America Dengue Vaccines, by Application USD Million (2017-2022)
  • Table 26. Rest of South America Dengue Vaccines, by End Users USD Million (2017-2022)
  • Table 27. Rest of South America Dengue Vaccines, by Vaccines USD Million (2017-2022)
  • Table 28. Asia Pacific Dengue Vaccines, by Country USD Million (2017-2022)
  • Table 29. Asia Pacific Dengue Vaccines, by Application USD Million (2017-2022)
  • Table 30. Asia Pacific Dengue Vaccines, by End Users USD Million (2017-2022)
  • Table 31. Asia Pacific Dengue Vaccines, by Vaccines USD Million (2017-2022)
  • Table 32. China Dengue Vaccines, by Application USD Million (2017-2022)
  • Table 33. China Dengue Vaccines, by End Users USD Million (2017-2022)
  • Table 34. China Dengue Vaccines, by Vaccines USD Million (2017-2022)
  • Table 35. Japan Dengue Vaccines, by Application USD Million (2017-2022)
  • Table 36. Japan Dengue Vaccines, by End Users USD Million (2017-2022)
  • Table 37. Japan Dengue Vaccines, by Vaccines USD Million (2017-2022)
  • Table 38. India Dengue Vaccines, by Application USD Million (2017-2022)
  • Table 39. India Dengue Vaccines, by End Users USD Million (2017-2022)
  • Table 40. India Dengue Vaccines, by Vaccines USD Million (2017-2022)
  • Table 41. South Korea Dengue Vaccines, by Application USD Million (2017-2022)
  • Table 42. South Korea Dengue Vaccines, by End Users USD Million (2017-2022)
  • Table 43. South Korea Dengue Vaccines, by Vaccines USD Million (2017-2022)
  • Table 44. Taiwan Dengue Vaccines, by Application USD Million (2017-2022)
  • Table 45. Taiwan Dengue Vaccines, by End Users USD Million (2017-2022)
  • Table 46. Taiwan Dengue Vaccines, by Vaccines USD Million (2017-2022)
  • Table 47. Australia Dengue Vaccines, by Application USD Million (2017-2022)
  • Table 48. Australia Dengue Vaccines, by End Users USD Million (2017-2022)
  • Table 49. Australia Dengue Vaccines, by Vaccines USD Million (2017-2022)
  • Table 50. Rest of Asia-Pacific Dengue Vaccines, by Application USD Million (2017-2022)
  • Table 51. Rest of Asia-Pacific Dengue Vaccines, by End Users USD Million (2017-2022)
  • Table 52. Rest of Asia-Pacific Dengue Vaccines, by Vaccines USD Million (2017-2022)
  • Table 53. Europe Dengue Vaccines, by Country USD Million (2017-2022)
  • Table 54. Europe Dengue Vaccines, by Application USD Million (2017-2022)
  • Table 55. Europe Dengue Vaccines, by End Users USD Million (2017-2022)
  • Table 56. Europe Dengue Vaccines, by Vaccines USD Million (2017-2022)
  • Table 57. Germany Dengue Vaccines, by Application USD Million (2017-2022)
  • Table 58. Germany Dengue Vaccines, by End Users USD Million (2017-2022)
  • Table 59. Germany Dengue Vaccines, by Vaccines USD Million (2017-2022)
  • Table 60. France Dengue Vaccines, by Application USD Million (2017-2022)
  • Table 61. France Dengue Vaccines, by End Users USD Million (2017-2022)
  • Table 62. France Dengue Vaccines, by Vaccines USD Million (2017-2022)
  • Table 63. Italy Dengue Vaccines, by Application USD Million (2017-2022)
  • Table 64. Italy Dengue Vaccines, by End Users USD Million (2017-2022)
  • Table 65. Italy Dengue Vaccines, by Vaccines USD Million (2017-2022)
  • Table 66. United Kingdom Dengue Vaccines, by Application USD Million (2017-2022)
  • Table 67. United Kingdom Dengue Vaccines, by End Users USD Million (2017-2022)
  • Table 68. United Kingdom Dengue Vaccines, by Vaccines USD Million (2017-2022)
  • Table 69. Netherlands Dengue Vaccines, by Application USD Million (2017-2022)
  • Table 70. Netherlands Dengue Vaccines, by End Users USD Million (2017-2022)
  • Table 71. Netherlands Dengue Vaccines, by Vaccines USD Million (2017-2022)
  • Table 72. Rest of Europe Dengue Vaccines, by Application USD Million (2017-2022)
  • Table 73. Rest of Europe Dengue Vaccines, by End Users USD Million (2017-2022)
  • Table 74. Rest of Europe Dengue Vaccines, by Vaccines USD Million (2017-2022)
  • Table 75. MEA Dengue Vaccines, by Country USD Million (2017-2022)
  • Table 76. MEA Dengue Vaccines, by Application USD Million (2017-2022)
  • Table 77. MEA Dengue Vaccines, by End Users USD Million (2017-2022)
  • Table 78. MEA Dengue Vaccines, by Vaccines USD Million (2017-2022)
  • Table 79. Middle East Dengue Vaccines, by Application USD Million (2017-2022)
  • Table 80. Middle East Dengue Vaccines, by End Users USD Million (2017-2022)
  • Table 81. Middle East Dengue Vaccines, by Vaccines USD Million (2017-2022)
  • Table 82. Africa Dengue Vaccines, by Application USD Million (2017-2022)
  • Table 83. Africa Dengue Vaccines, by End Users USD Million (2017-2022)
  • Table 84. Africa Dengue Vaccines, by Vaccines USD Million (2017-2022)
  • Table 85. North America Dengue Vaccines, by Country USD Million (2017-2022)
  • Table 86. North America Dengue Vaccines, by Application USD Million (2017-2022)
  • Table 87. North America Dengue Vaccines, by End Users USD Million (2017-2022)
  • Table 88. North America Dengue Vaccines, by Vaccines USD Million (2017-2022)
  • Table 89. United States Dengue Vaccines, by Application USD Million (2017-2022)
  • Table 90. United States Dengue Vaccines, by End Users USD Million (2017-2022)
  • Table 91. United States Dengue Vaccines, by Vaccines USD Million (2017-2022)
  • Table 92. Canada Dengue Vaccines, by Application USD Million (2017-2022)
  • Table 93. Canada Dengue Vaccines, by End Users USD Million (2017-2022)
  • Table 94. Canada Dengue Vaccines, by Vaccines USD Million (2017-2022)
  • Table 95. Mexico Dengue Vaccines, by Application USD Million (2017-2022)
  • Table 96. Mexico Dengue Vaccines, by End Users USD Million (2017-2022)
  • Table 97. Mexico Dengue Vaccines, by Vaccines USD Million (2017-2022)
  • Table 98. Dengue Vaccines Sales: by Application(K Units)
  • Table 99. Dengue Vaccines Sales Prevention of dengue , by Region K Units (2017-2022)
  • Table 100. Dengue Vaccines Sales Enhanced the immunity , by Region K Units (2017-2022)
  • Table 101. Dengue Vaccines Sales: by End Users(K Units)
  • Table 102. Dengue Vaccines Sales Government organizations , by Region K Units (2017-2022)
  • Table 103. Dengue Vaccines Sales Medical clinics , by Region K Units (2017-2022)
  • Table 104. Dengue Vaccines Sales Non-profit Organization , by Region K Units (2017-2022)
  • Table 105. Dengue Vaccines Sales Diagnostic centers , by Region K Units (2017-2022)
  • Table 106. Dengue Vaccines Sales: by Vaccines(K Units)
  • Table 107. Dengue Vaccines Sales Live Attenuated Vaccines , by Region K Units (2017-2022)
  • Table 108. Dengue Vaccines Sales Chimeric Live Attenuated Vaccines , by Region K Units (2017-2022)
  • Table 109. Dengue Vaccines Sales Inactivated Vaccines , by Region K Units (2017-2022)
  • Table 110. Dengue Vaccines Sales Subunit Vaccines , by Region K Units (2017-2022)
  • Table 111. Dengue Vaccines Sales Nucleic Acid-Based Vaccines , by Region K Units (2017-2022)
  • Table 112. South America Dengue Vaccines Sales, by Country K Units (2017-2022)
  • Table 113. South America Dengue Vaccines Sales, by Application K Units (2017-2022)
  • Table 114. South America Dengue Vaccines Sales, by End Users K Units (2017-2022)
  • Table 115. South America Dengue Vaccines Sales, by Vaccines K Units (2017-2022)
  • Table 116. Brazil Dengue Vaccines Sales, by Application K Units (2017-2022)
  • Table 117. Brazil Dengue Vaccines Sales, by End Users K Units (2017-2022)
  • Table 118. Brazil Dengue Vaccines Sales, by Vaccines K Units (2017-2022)
  • Table 119. Argentina Dengue Vaccines Sales, by Application K Units (2017-2022)
  • Table 120. Argentina Dengue Vaccines Sales, by End Users K Units (2017-2022)
  • Table 121. Argentina Dengue Vaccines Sales, by Vaccines K Units (2017-2022)
  • Table 122. Rest of South America Dengue Vaccines Sales, by Application K Units (2017-2022)
  • Table 123. Rest of South America Dengue Vaccines Sales, by End Users K Units (2017-2022)
  • Table 124. Rest of South America Dengue Vaccines Sales, by Vaccines K Units (2017-2022)
  • Table 125. Asia Pacific Dengue Vaccines Sales, by Country K Units (2017-2022)
  • Table 126. Asia Pacific Dengue Vaccines Sales, by Application K Units (2017-2022)
  • Table 127. Asia Pacific Dengue Vaccines Sales, by End Users K Units (2017-2022)
  • Table 128. Asia Pacific Dengue Vaccines Sales, by Vaccines K Units (2017-2022)
  • Table 129. China Dengue Vaccines Sales, by Application K Units (2017-2022)
  • Table 130. China Dengue Vaccines Sales, by End Users K Units (2017-2022)
  • Table 131. China Dengue Vaccines Sales, by Vaccines K Units (2017-2022)
  • Table 132. Japan Dengue Vaccines Sales, by Application K Units (2017-2022)
  • Table 133. Japan Dengue Vaccines Sales, by End Users K Units (2017-2022)
  • Table 134. Japan Dengue Vaccines Sales, by Vaccines K Units (2017-2022)
  • Table 135. India Dengue Vaccines Sales, by Application K Units (2017-2022)
  • Table 136. India Dengue Vaccines Sales, by End Users K Units (2017-2022)
  • Table 137. India Dengue Vaccines Sales, by Vaccines K Units (2017-2022)
  • Table 138. South Korea Dengue Vaccines Sales, by Application K Units (2017-2022)
  • Table 139. South Korea Dengue Vaccines Sales, by End Users K Units (2017-2022)
  • Table 140. South Korea Dengue Vaccines Sales, by Vaccines K Units (2017-2022)
  • Table 141. Taiwan Dengue Vaccines Sales, by Application K Units (2017-2022)
  • Table 142. Taiwan Dengue Vaccines Sales, by End Users K Units (2017-2022)
  • Table 143. Taiwan Dengue Vaccines Sales, by Vaccines K Units (2017-2022)
  • Table 144. Australia Dengue Vaccines Sales, by Application K Units (2017-2022)
  • Table 145. Australia Dengue Vaccines Sales, by End Users K Units (2017-2022)
  • Table 146. Australia Dengue Vaccines Sales, by Vaccines K Units (2017-2022)
  • Table 147. Rest of Asia-Pacific Dengue Vaccines Sales, by Application K Units (2017-2022)
  • Table 148. Rest of Asia-Pacific Dengue Vaccines Sales, by End Users K Units (2017-2022)
  • Table 149. Rest of Asia-Pacific Dengue Vaccines Sales, by Vaccines K Units (2017-2022)
  • Table 150. Europe Dengue Vaccines Sales, by Country K Units (2017-2022)
  • Table 151. Europe Dengue Vaccines Sales, by Application K Units (2017-2022)
  • Table 152. Europe Dengue Vaccines Sales, by End Users K Units (2017-2022)
  • Table 153. Europe Dengue Vaccines Sales, by Vaccines K Units (2017-2022)
  • Table 154. Germany Dengue Vaccines Sales, by Application K Units (2017-2022)
  • Table 155. Germany Dengue Vaccines Sales, by End Users K Units (2017-2022)
  • Table 156. Germany Dengue Vaccines Sales, by Vaccines K Units (2017-2022)
  • Table 157. France Dengue Vaccines Sales, by Application K Units (2017-2022)
  • Table 158. France Dengue Vaccines Sales, by End Users K Units (2017-2022)
  • Table 159. France Dengue Vaccines Sales, by Vaccines K Units (2017-2022)
  • Table 160. Italy Dengue Vaccines Sales, by Application K Units (2017-2022)
  • Table 161. Italy Dengue Vaccines Sales, by End Users K Units (2017-2022)
  • Table 162. Italy Dengue Vaccines Sales, by Vaccines K Units (2017-2022)
  • Table 163. United Kingdom Dengue Vaccines Sales, by Application K Units (2017-2022)
  • Table 164. United Kingdom Dengue Vaccines Sales, by End Users K Units (2017-2022)
  • Table 165. United Kingdom Dengue Vaccines Sales, by Vaccines K Units (2017-2022)
  • Table 166. Netherlands Dengue Vaccines Sales, by Application K Units (2017-2022)
  • Table 167. Netherlands Dengue Vaccines Sales, by End Users K Units (2017-2022)
  • Table 168. Netherlands Dengue Vaccines Sales, by Vaccines K Units (2017-2022)
  • Table 169. Rest of Europe Dengue Vaccines Sales, by Application K Units (2017-2022)
  • Table 170. Rest of Europe Dengue Vaccines Sales, by End Users K Units (2017-2022)
  • Table 171. Rest of Europe Dengue Vaccines Sales, by Vaccines K Units (2017-2022)
  • Table 172. MEA Dengue Vaccines Sales, by Country K Units (2017-2022)
  • Table 173. MEA Dengue Vaccines Sales, by Application K Units (2017-2022)
  • Table 174. MEA Dengue Vaccines Sales, by End Users K Units (2017-2022)
  • Table 175. MEA Dengue Vaccines Sales, by Vaccines K Units (2017-2022)
  • Table 176. Middle East Dengue Vaccines Sales, by Application K Units (2017-2022)
  • Table 177. Middle East Dengue Vaccines Sales, by End Users K Units (2017-2022)
  • Table 178. Middle East Dengue Vaccines Sales, by Vaccines K Units (2017-2022)
  • Table 179. Africa Dengue Vaccines Sales, by Application K Units (2017-2022)
  • Table 180. Africa Dengue Vaccines Sales, by End Users K Units (2017-2022)
  • Table 181. Africa Dengue Vaccines Sales, by Vaccines K Units (2017-2022)
  • Table 182. North America Dengue Vaccines Sales, by Country K Units (2017-2022)
  • Table 183. North America Dengue Vaccines Sales, by Application K Units (2017-2022)
  • Table 184. North America Dengue Vaccines Sales, by End Users K Units (2017-2022)
  • Table 185. North America Dengue Vaccines Sales, by Vaccines K Units (2017-2022)
  • Table 186. United States Dengue Vaccines Sales, by Application K Units (2017-2022)
  • Table 187. United States Dengue Vaccines Sales, by End Users K Units (2017-2022)
  • Table 188. United States Dengue Vaccines Sales, by Vaccines K Units (2017-2022)
  • Table 189. Canada Dengue Vaccines Sales, by Application K Units (2017-2022)
  • Table 190. Canada Dengue Vaccines Sales, by End Users K Units (2017-2022)
  • Table 191. Canada Dengue Vaccines Sales, by Vaccines K Units (2017-2022)
  • Table 192. Mexico Dengue Vaccines Sales, by Application K Units (2017-2022)
  • Table 193. Mexico Dengue Vaccines Sales, by End Users K Units (2017-2022)
  • Table 194. Mexico Dengue Vaccines Sales, by Vaccines K Units (2017-2022)
  • Table 195. Company Basic Information, Sales Area and Its Competitors
  • Table 196. Company Basic Information, Sales Area and Its Competitors
  • Table 197. Company Basic Information, Sales Area and Its Competitors
  • Table 198. Company Basic Information, Sales Area and Its Competitors
  • Table 199. Company Basic Information, Sales Area and Its Competitors
  • Table 200. Company Basic Information, Sales Area and Its Competitors
  • Table 201. Company Basic Information, Sales Area and Its Competitors
  • Table 202. Company Basic Information, Sales Area and Its Competitors
  • Table 203. Company Basic Information, Sales Area and Its Competitors
  • Table 204. Company Basic Information, Sales Area and Its Competitors
  • Table 205. Dengue Vaccines: by Application(USD Million)
  • Table 206. Dengue Vaccines Prevention of dengue , by Region USD Million (2023-2028)
  • Table 207. Dengue Vaccines Enhanced the immunity , by Region USD Million (2023-2028)
  • Table 208. Dengue Vaccines: by End Users(USD Million)
  • Table 209. Dengue Vaccines Government organizations , by Region USD Million (2023-2028)
  • Table 210. Dengue Vaccines Medical clinics , by Region USD Million (2023-2028)
  • Table 211. Dengue Vaccines Non-profit Organization , by Region USD Million (2023-2028)
  • Table 212. Dengue Vaccines Diagnostic centers , by Region USD Million (2023-2028)
  • Table 213. Dengue Vaccines: by Vaccines(USD Million)
  • Table 214. Dengue Vaccines Live Attenuated Vaccines , by Region USD Million (2023-2028)
  • Table 215. Dengue Vaccines Chimeric Live Attenuated Vaccines , by Region USD Million (2023-2028)
  • Table 216. Dengue Vaccines Inactivated Vaccines , by Region USD Million (2023-2028)
  • Table 217. Dengue Vaccines Subunit Vaccines , by Region USD Million (2023-2028)
  • Table 218. Dengue Vaccines Nucleic Acid-Based Vaccines , by Region USD Million (2023-2028)
  • Table 219. South America Dengue Vaccines, by Country USD Million (2023-2028)
  • Table 220. South America Dengue Vaccines, by Application USD Million (2023-2028)
  • Table 221. South America Dengue Vaccines, by End Users USD Million (2023-2028)
  • Table 222. South America Dengue Vaccines, by Vaccines USD Million (2023-2028)
  • Table 223. Brazil Dengue Vaccines, by Application USD Million (2023-2028)
  • Table 224. Brazil Dengue Vaccines, by End Users USD Million (2023-2028)
  • Table 225. Brazil Dengue Vaccines, by Vaccines USD Million (2023-2028)
  • Table 226. Argentina Dengue Vaccines, by Application USD Million (2023-2028)
  • Table 227. Argentina Dengue Vaccines, by End Users USD Million (2023-2028)
  • Table 228. Argentina Dengue Vaccines, by Vaccines USD Million (2023-2028)
  • Table 229. Rest of South America Dengue Vaccines, by Application USD Million (2023-2028)
  • Table 230. Rest of South America Dengue Vaccines, by End Users USD Million (2023-2028)
  • Table 231. Rest of South America Dengue Vaccines, by Vaccines USD Million (2023-2028)
  • Table 232. Asia Pacific Dengue Vaccines, by Country USD Million (2023-2028)
  • Table 233. Asia Pacific Dengue Vaccines, by Application USD Million (2023-2028)
  • Table 234. Asia Pacific Dengue Vaccines, by End Users USD Million (2023-2028)
  • Table 235. Asia Pacific Dengue Vaccines, by Vaccines USD Million (2023-2028)
  • Table 236. China Dengue Vaccines, by Application USD Million (2023-2028)
  • Table 237. China Dengue Vaccines, by End Users USD Million (2023-2028)
  • Table 238. China Dengue Vaccines, by Vaccines USD Million (2023-2028)
  • Table 239. Japan Dengue Vaccines, by Application USD Million (2023-2028)
  • Table 240. Japan Dengue Vaccines, by End Users USD Million (2023-2028)
  • Table 241. Japan Dengue Vaccines, by Vaccines USD Million (2023-2028)
  • Table 242. India Dengue Vaccines, by Application USD Million (2023-2028)
  • Table 243. India Dengue Vaccines, by End Users USD Million (2023-2028)
  • Table 244. India Dengue Vaccines, by Vaccines USD Million (2023-2028)
  • Table 245. South Korea Dengue Vaccines, by Application USD Million (2023-2028)
  • Table 246. South Korea Dengue Vaccines, by End Users USD Million (2023-2028)
  • Table 247. South Korea Dengue Vaccines, by Vaccines USD Million (2023-2028)
  • Table 248. Taiwan Dengue Vaccines, by Application USD Million (2023-2028)
  • Table 249. Taiwan Dengue Vaccines, by End Users USD Million (2023-2028)
  • Table 250. Taiwan Dengue Vaccines, by Vaccines USD Million (2023-2028)
  • Table 251. Australia Dengue Vaccines, by Application USD Million (2023-2028)
  • Table 252. Australia Dengue Vaccines, by End Users USD Million (2023-2028)
  • Table 253. Australia Dengue Vaccines, by Vaccines USD Million (2023-2028)
  • Table 254. Rest of Asia-Pacific Dengue Vaccines, by Application USD Million (2023-2028)
  • Table 255. Rest of Asia-Pacific Dengue Vaccines, by End Users USD Million (2023-2028)
  • Table 256. Rest of Asia-Pacific Dengue Vaccines, by Vaccines USD Million (2023-2028)
  • Table 257. Europe Dengue Vaccines, by Country USD Million (2023-2028)
  • Table 258. Europe Dengue Vaccines, by Application USD Million (2023-2028)
  • Table 259. Europe Dengue Vaccines, by End Users USD Million (2023-2028)
  • Table 260. Europe Dengue Vaccines, by Vaccines USD Million (2023-2028)
  • Table 261. Germany Dengue Vaccines, by Application USD Million (2023-2028)
  • Table 262. Germany Dengue Vaccines, by End Users USD Million (2023-2028)
  • Table 263. Germany Dengue Vaccines, by Vaccines USD Million (2023-2028)
  • Table 264. France Dengue Vaccines, by Application USD Million (2023-2028)
  • Table 265. France Dengue Vaccines, by End Users USD Million (2023-2028)
  • Table 266. France Dengue Vaccines, by Vaccines USD Million (2023-2028)
  • Table 267. Italy Dengue Vaccines, by Application USD Million (2023-2028)
  • Table 268. Italy Dengue Vaccines, by End Users USD Million (2023-2028)
  • Table 269. Italy Dengue Vaccines, by Vaccines USD Million (2023-2028)
  • Table 270. United Kingdom Dengue Vaccines, by Application USD Million (2023-2028)
  • Table 271. United Kingdom Dengue Vaccines, by End Users USD Million (2023-2028)
  • Table 272. United Kingdom Dengue Vaccines, by Vaccines USD Million (2023-2028)
  • Table 273. Netherlands Dengue Vaccines, by Application USD Million (2023-2028)
  • Table 274. Netherlands Dengue Vaccines, by End Users USD Million (2023-2028)
  • Table 275. Netherlands Dengue Vaccines, by Vaccines USD Million (2023-2028)
  • Table 276. Rest of Europe Dengue Vaccines, by Application USD Million (2023-2028)
  • Table 277. Rest of Europe Dengue Vaccines, by End Users USD Million (2023-2028)
  • Table 278. Rest of Europe Dengue Vaccines, by Vaccines USD Million (2023-2028)
  • Table 279. MEA Dengue Vaccines, by Country USD Million (2023-2028)
  • Table 280. MEA Dengue Vaccines, by Application USD Million (2023-2028)
  • Table 281. MEA Dengue Vaccines, by End Users USD Million (2023-2028)
  • Table 282. MEA Dengue Vaccines, by Vaccines USD Million (2023-2028)
  • Table 283. Middle East Dengue Vaccines, by Application USD Million (2023-2028)
  • Table 284. Middle East Dengue Vaccines, by End Users USD Million (2023-2028)
  • Table 285. Middle East Dengue Vaccines, by Vaccines USD Million (2023-2028)
  • Table 286. Africa Dengue Vaccines, by Application USD Million (2023-2028)
  • Table 287. Africa Dengue Vaccines, by End Users USD Million (2023-2028)
  • Table 288. Africa Dengue Vaccines, by Vaccines USD Million (2023-2028)
  • Table 289. North America Dengue Vaccines, by Country USD Million (2023-2028)
  • Table 290. North America Dengue Vaccines, by Application USD Million (2023-2028)
  • Table 291. North America Dengue Vaccines, by End Users USD Million (2023-2028)
  • Table 292. North America Dengue Vaccines, by Vaccines USD Million (2023-2028)
  • Table 293. United States Dengue Vaccines, by Application USD Million (2023-2028)
  • Table 294. United States Dengue Vaccines, by End Users USD Million (2023-2028)
  • Table 295. United States Dengue Vaccines, by Vaccines USD Million (2023-2028)
  • Table 296. Canada Dengue Vaccines, by Application USD Million (2023-2028)
  • Table 297. Canada Dengue Vaccines, by End Users USD Million (2023-2028)
  • Table 298. Canada Dengue Vaccines, by Vaccines USD Million (2023-2028)
  • Table 299. Mexico Dengue Vaccines, by Application USD Million (2023-2028)
  • Table 300. Mexico Dengue Vaccines, by End Users USD Million (2023-2028)
  • Table 301. Mexico Dengue Vaccines, by Vaccines USD Million (2023-2028)
  • Table 302. Dengue Vaccines Sales: by Application(K Units)
  • Table 303. Dengue Vaccines Sales Prevention of dengue , by Region K Units (2023-2028)
  • Table 304. Dengue Vaccines Sales Enhanced the immunity , by Region K Units (2023-2028)
  • Table 305. Dengue Vaccines Sales: by End Users(K Units)
  • Table 306. Dengue Vaccines Sales Government organizations , by Region K Units (2023-2028)
  • Table 307. Dengue Vaccines Sales Medical clinics , by Region K Units (2023-2028)
  • Table 308. Dengue Vaccines Sales Non-profit Organization , by Region K Units (2023-2028)
  • Table 309. Dengue Vaccines Sales Diagnostic centers , by Region K Units (2023-2028)
  • Table 310. Dengue Vaccines Sales: by Vaccines(K Units)
  • Table 311. Dengue Vaccines Sales Live Attenuated Vaccines , by Region K Units (2023-2028)
  • Table 312. Dengue Vaccines Sales Chimeric Live Attenuated Vaccines , by Region K Units (2023-2028)
  • Table 313. Dengue Vaccines Sales Inactivated Vaccines , by Region K Units (2023-2028)
  • Table 314. Dengue Vaccines Sales Subunit Vaccines , by Region K Units (2023-2028)
  • Table 315. Dengue Vaccines Sales Nucleic Acid-Based Vaccines , by Region K Units (2023-2028)
  • Table 316. South America Dengue Vaccines Sales, by Country K Units (2023-2028)
  • Table 317. South America Dengue Vaccines Sales, by Application K Units (2023-2028)
  • Table 318. South America Dengue Vaccines Sales, by End Users K Units (2023-2028)
  • Table 319. South America Dengue Vaccines Sales, by Vaccines K Units (2023-2028)
  • Table 320. Brazil Dengue Vaccines Sales, by Application K Units (2023-2028)
  • Table 321. Brazil Dengue Vaccines Sales, by End Users K Units (2023-2028)
  • Table 322. Brazil Dengue Vaccines Sales, by Vaccines K Units (2023-2028)
  • Table 323. Argentina Dengue Vaccines Sales, by Application K Units (2023-2028)
  • Table 324. Argentina Dengue Vaccines Sales, by End Users K Units (2023-2028)
  • Table 325. Argentina Dengue Vaccines Sales, by Vaccines K Units (2023-2028)
  • Table 326. Rest of South America Dengue Vaccines Sales, by Application K Units (2023-2028)
  • Table 327. Rest of South America Dengue Vaccines Sales, by End Users K Units (2023-2028)
  • Table 328. Rest of South America Dengue Vaccines Sales, by Vaccines K Units (2023-2028)
  • Table 329. Asia Pacific Dengue Vaccines Sales, by Country K Units (2023-2028)
  • Table 330. Asia Pacific Dengue Vaccines Sales, by Application K Units (2023-2028)
  • Table 331. Asia Pacific Dengue Vaccines Sales, by End Users K Units (2023-2028)
  • Table 332. Asia Pacific Dengue Vaccines Sales, by Vaccines K Units (2023-2028)
  • Table 333. China Dengue Vaccines Sales, by Application K Units (2023-2028)
  • Table 334. China Dengue Vaccines Sales, by End Users K Units (2023-2028)
  • Table 335. China Dengue Vaccines Sales, by Vaccines K Units (2023-2028)
  • Table 336. Japan Dengue Vaccines Sales, by Application K Units (2023-2028)
  • Table 337. Japan Dengue Vaccines Sales, by End Users K Units (2023-2028)
  • Table 338. Japan Dengue Vaccines Sales, by Vaccines K Units (2023-2028)
  • Table 339. India Dengue Vaccines Sales, by Application K Units (2023-2028)
  • Table 340. India Dengue Vaccines Sales, by End Users K Units (2023-2028)
  • Table 341. India Dengue Vaccines Sales, by Vaccines K Units (2023-2028)
  • Table 342. South Korea Dengue Vaccines Sales, by Application K Units (2023-2028)
  • Table 343. South Korea Dengue Vaccines Sales, by End Users K Units (2023-2028)
  • Table 344. South Korea Dengue Vaccines Sales, by Vaccines K Units (2023-2028)
  • Table 345. Taiwan Dengue Vaccines Sales, by Application K Units (2023-2028)
  • Table 346. Taiwan Dengue Vaccines Sales, by End Users K Units (2023-2028)
  • Table 347. Taiwan Dengue Vaccines Sales, by Vaccines K Units (2023-2028)
  • Table 348. Australia Dengue Vaccines Sales, by Application K Units (2023-2028)
  • Table 349. Australia Dengue Vaccines Sales, by End Users K Units (2023-2028)
  • Table 350. Australia Dengue Vaccines Sales, by Vaccines K Units (2023-2028)
  • Table 351. Rest of Asia-Pacific Dengue Vaccines Sales, by Application K Units (2023-2028)
  • Table 352. Rest of Asia-Pacific Dengue Vaccines Sales, by End Users K Units (2023-2028)
  • Table 353. Rest of Asia-Pacific Dengue Vaccines Sales, by Vaccines K Units (2023-2028)
  • Table 354. Europe Dengue Vaccines Sales, by Country K Units (2023-2028)
  • Table 355. Europe Dengue Vaccines Sales, by Application K Units (2023-2028)
  • Table 356. Europe Dengue Vaccines Sales, by End Users K Units (2023-2028)
  • Table 357. Europe Dengue Vaccines Sales, by Vaccines K Units (2023-2028)
  • Table 358. Germany Dengue Vaccines Sales, by Application K Units (2023-2028)
  • Table 359. Germany Dengue Vaccines Sales, by End Users K Units (2023-2028)
  • Table 360. Germany Dengue Vaccines Sales, by Vaccines K Units (2023-2028)
  • Table 361. France Dengue Vaccines Sales, by Application K Units (2023-2028)
  • Table 362. France Dengue Vaccines Sales, by End Users K Units (2023-2028)
  • Table 363. France Dengue Vaccines Sales, by Vaccines K Units (2023-2028)
  • Table 364. Italy Dengue Vaccines Sales, by Application K Units (2023-2028)
  • Table 365. Italy Dengue Vaccines Sales, by End Users K Units (2023-2028)
  • Table 366. Italy Dengue Vaccines Sales, by Vaccines K Units (2023-2028)
  • Table 367. United Kingdom Dengue Vaccines Sales, by Application K Units (2023-2028)
  • Table 368. United Kingdom Dengue Vaccines Sales, by End Users K Units (2023-2028)
  • Table 369. United Kingdom Dengue Vaccines Sales, by Vaccines K Units (2023-2028)
  • Table 370. Netherlands Dengue Vaccines Sales, by Application K Units (2023-2028)
  • Table 371. Netherlands Dengue Vaccines Sales, by End Users K Units (2023-2028)
  • Table 372. Netherlands Dengue Vaccines Sales, by Vaccines K Units (2023-2028)
  • Table 373. Rest of Europe Dengue Vaccines Sales, by Application K Units (2023-2028)
  • Table 374. Rest of Europe Dengue Vaccines Sales, by End Users K Units (2023-2028)
  • Table 375. Rest of Europe Dengue Vaccines Sales, by Vaccines K Units (2023-2028)
  • Table 376. MEA Dengue Vaccines Sales, by Country K Units (2023-2028)
  • Table 377. MEA Dengue Vaccines Sales, by Application K Units (2023-2028)
  • Table 378. MEA Dengue Vaccines Sales, by End Users K Units (2023-2028)
  • Table 379. MEA Dengue Vaccines Sales, by Vaccines K Units (2023-2028)
  • Table 380. Middle East Dengue Vaccines Sales, by Application K Units (2023-2028)
  • Table 381. Middle East Dengue Vaccines Sales, by End Users K Units (2023-2028)
  • Table 382. Middle East Dengue Vaccines Sales, by Vaccines K Units (2023-2028)
  • Table 383. Africa Dengue Vaccines Sales, by Application K Units (2023-2028)
  • Table 384. Africa Dengue Vaccines Sales, by End Users K Units (2023-2028)
  • Table 385. Africa Dengue Vaccines Sales, by Vaccines K Units (2023-2028)
  • Table 386. North America Dengue Vaccines Sales, by Country K Units (2023-2028)
  • Table 387. North America Dengue Vaccines Sales, by Application K Units (2023-2028)
  • Table 388. North America Dengue Vaccines Sales, by End Users K Units (2023-2028)
  • Table 389. North America Dengue Vaccines Sales, by Vaccines K Units (2023-2028)
  • Table 390. United States Dengue Vaccines Sales, by Application K Units (2023-2028)
  • Table 391. United States Dengue Vaccines Sales, by End Users K Units (2023-2028)
  • Table 392. United States Dengue Vaccines Sales, by Vaccines K Units (2023-2028)
  • Table 393. Canada Dengue Vaccines Sales, by Application K Units (2023-2028)
  • Table 394. Canada Dengue Vaccines Sales, by End Users K Units (2023-2028)
  • Table 395. Canada Dengue Vaccines Sales, by Vaccines K Units (2023-2028)
  • Table 396. Mexico Dengue Vaccines Sales, by Application K Units (2023-2028)
  • Table 397. Mexico Dengue Vaccines Sales, by End Users K Units (2023-2028)
  • Table 398. Mexico Dengue Vaccines Sales, by Vaccines K Units (2023-2028)
  • Table 399. Research Programs/Design for This Report
  • Table 400. Key Data Information from Secondary Sources
  • Table 401. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Dengue Vaccines: by Application USD Million (2017-2022)
  • Figure 5. Global Dengue Vaccines: by End Users USD Million (2017-2022)
  • Figure 6. Global Dengue Vaccines: by Vaccines USD Million (2017-2022)
  • Figure 7. South America Dengue Vaccines Share (%), by Country
  • Figure 8. Asia Pacific Dengue Vaccines Share (%), by Country
  • Figure 9. Europe Dengue Vaccines Share (%), by Country
  • Figure 10. MEA Dengue Vaccines Share (%), by Country
  • Figure 11. North America Dengue Vaccines Share (%), by Country
  • Figure 12. Global Dengue Vaccines: by Application K Units (2017-2022)
  • Figure 13. Global Dengue Vaccines: by End Users K Units (2017-2022)
  • Figure 14. Global Dengue Vaccines: by Vaccines K Units (2017-2022)
  • Figure 15. South America Dengue Vaccines Share (%), by Country
  • Figure 16. Asia Pacific Dengue Vaccines Share (%), by Country
  • Figure 17. Europe Dengue Vaccines Share (%), by Country
  • Figure 18. MEA Dengue Vaccines Share (%), by Country
  • Figure 19. North America Dengue Vaccines Share (%), by Country
  • Figure 20. Global Dengue Vaccines share by Players 2022 (%)
  • Figure 21. Global Dengue Vaccines share by Players (Top 3) 2022(%)
  • Figure 22. Global Dengue Vaccines share by Players (Top 5) 2022(%)
  • Figure 23. BCG Matrix for key Companies
  • Figure 24. Sanofi Pasteur Inc (France) Revenue, Net Income and Gross profit
  • Figure 25. Sanofi Pasteur Inc (France) Revenue: by Geography 2022
  • Figure 26. Merck & Co Inc (United States) Revenue, Net Income and Gross profit
  • Figure 27. Merck & Co Inc (United States) Revenue: by Geography 2022
  • Figure 28. GlaxoSmithKline (United Kingdom ) Revenue, Net Income and Gross profit
  • Figure 29. GlaxoSmithKline (United Kingdom ) Revenue: by Geography 2022
  • Figure 30. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 31. Pfizer (United States) Revenue: by Geography 2022
  • Figure 32. Instituto Butantan (Brazil) Revenue, Net Income and Gross profit
  • Figure 33. Instituto Butantan (Brazil) Revenue: by Geography 2022
  • Figure 34. Takeda Pharmaceutical Company Limited (Japan) Revenue, Net Income and Gross profit
  • Figure 35. Takeda Pharmaceutical Company Limited (Japan) Revenue: by Geography 2022
  • Figure 36. Sun Pharmaceutical Industries Limited (India) Revenue, Net Income and Gross profit
  • Figure 37. Sun Pharmaceutical Industries Limited (India) Revenue: by Geography 2022
  • Figure 38. GeneOne Life Science Inc (South Korea) Revenue, Net Income and Gross profit
  • Figure 39. GeneOne Life Science Inc (South Korea) Revenue: by Geography 2022
  • Figure 40. Medigen Vaccine Biologics Corporation (China) Revenue, Net Income and Gross profit
  • Figure 41. Medigen Vaccine Biologics Corporation (China) Revenue: by Geography 2022
  • Figure 42. Merck Sharp & Dohme (United States) Revenue, Net Income and Gross profit
  • Figure 43. Merck Sharp & Dohme (United States) Revenue: by Geography 2022
  • Figure 44. Global Dengue Vaccines: by Application USD Million (2023-2028)
  • Figure 45. Global Dengue Vaccines: by End Users USD Million (2023-2028)
  • Figure 46. Global Dengue Vaccines: by Vaccines USD Million (2023-2028)
  • Figure 47. South America Dengue Vaccines Share (%), by Country
  • Figure 48. Asia Pacific Dengue Vaccines Share (%), by Country
  • Figure 49. Europe Dengue Vaccines Share (%), by Country
  • Figure 50. MEA Dengue Vaccines Share (%), by Country
  • Figure 51. North America Dengue Vaccines Share (%), by Country
  • Figure 52. Global Dengue Vaccines: by Application K Units (2023-2028)
  • Figure 53. Global Dengue Vaccines: by End Users K Units (2023-2028)
  • Figure 54. Global Dengue Vaccines: by Vaccines K Units (2023-2028)
  • Figure 55. South America Dengue Vaccines Share (%), by Country
  • Figure 56. Asia Pacific Dengue Vaccines Share (%), by Country
  • Figure 57. Europe Dengue Vaccines Share (%), by Country
  • Figure 58. MEA Dengue Vaccines Share (%), by Country
  • Figure 59. North America Dengue Vaccines Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Sanofi Pasteur Inc (France)
  • Merck & Co Inc (United States)
  • GlaxoSmithKline (United Kingdom )
  • Pfizer (United States)
  • Instituto Butantan (Brazil)
  • Takeda Pharmaceutical Company Limited (Japan)
  • Sun Pharmaceutical Industries Limited (India)
  • GeneOne Life Science Inc (South Korea)
  • Medigen Vaccine Biologics Corporation (China)
  • Merck Sharp & Dohme (United States)
Additional players considered in the study are as follows:
Vabiotec (Vietnam) , Panacea Biotec Limited (India) ,
Select User Access Type

Key Highlights of Report


Dec 2023 205 Pages 67 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Dengue Vaccines Quantitative research analysis
Global Dengue Vaccines Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Sanofi Pasteur Inc (France), Merck & Co Inc (United States), GlaxoSmithKline (United Kingdom ), Pfizer (United States), Instituto Butantan (Brazil), Takeda Pharmaceutical Company Limited (Japan), Sun Pharmaceutical Industries Limited (India), GeneOne Life Science Inc (South Korea), Medigen Vaccine Biologics Corporation (China) and Merck Sharp & Dohme (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Two New Live Attenuated Dengue Vaccines Are Currently In Phase Iii Efficacy Trials " is seen as one of major influencing trends for Dengue Vaccines Market during projected period 2022-2028.
The Dengue Vaccines market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Dengue Vaccines Report?

Have a Query? Click Here

Other Related Reports

Sample Preparation Comprehensive Study by Type (Sample preparation instruments, Consumables, Sample preparation kits, Accessories), Application (Pharmaceutical industries, Biotechnology, Diagnostic l...
$ 3750
Gout Therapeutics Comprehensive Study by Type (NSAIDs, Corticosteroids, Colchicine, Urate-Lowering Agents), Application (Hospitals, Clinics), Diseases Type (Acute Gout, Chronic Gout) Players and Regi...
$ 3500
Air Ambulance Services Comprehensive Study by Mission Profile (Inter Facility Transport, Scene Response, Others), Service Model (Community Based, Hospital Based, Hybrid), Aircraft Type (Fixed Wing ...
$ 3350
Health Information Systems Comprehensive Study by Application (Electronic Health Record, Real-Time Healthcare, Population Health Management, Transfer of Information), End Users (Hospitals, Pharmacy, ...
$ 3650
Energy Management Systems for Healthcare Comprehensive Study by Type (Inpatient, Outpatient), Application (Residential, Commercial, Public Buildings), Service (Monitoring & Control, Implementation & ...
$ 3650
Dental Implants Comprehensive Study by Type (Endosteal, Subperiosteal, Bone augmentation, Sinus lift, Ridge expansion), Application (Hospitals & Clinics, Dental Clinics, Others), Material implant typ...
$ 3350